Baxter 3Q Net Plunges After Kidney-Unit Sale, North Carolina Facility Shutdown

Dow Jones
2024/11/08
 

By Rob Curran

 

Medical-device maker Baxter International booked a plunge in third-quarter net income due to the divestiture of its dialysis-machine unit, and forecast fourth-quarter adjusted profit more or less flat sequentially, as it endeavored to get a factory back online in the wake of Hurricane Helene.

The Deerfield, Ill., maker of hospital supplies and other health-care items posted third-quarter earnings of $140 million, or 27 cents a share, down from $2.51 billion, or $4.93 a share, a year earlier. The year-earlier quarter included $4.86 a share in earnings attributable to the kidney-care unit, now categorized as discontinued operations.

In August, Baxter agreed to sell its Kidney Care unit for $3.8 billion to investment firm Carlyle Group. Baxter expects to receive about $3.15 billion-to-$3.25 billion in proceeds, net of tax.

Stripping out certain one-off items, Baxter logged adjusted earnings of 80 cents a share, topping the average Wall Street peg of 78 cents a share, according to a FactSet tally.

Third-quarter sales were $3.85 billion, in line with the average Wall Street target, as per FactSet.

For the fourth quarter, Baxter targeted adjusted earnings in a range between 77 cents and 81 cents a share. For 2024, Baxter projected adjusted earnings of $2.90-to-$2.94 a share.

"While the hurricane's aftermath is expected to have an impact on our near-term financial outlook, we remain confident in Baxter's outlook and growth trajectory following completion of the pending Kidney Care sale," Chairman, President and Chief Executive Jose Almeida said in a statement.

Hurricane Helene, which hit North Carolina in late September, flooded Baxter's North Cove, N.C., manufacturing facility, leading to a temporary production shutdown.

Baxter said it is working to restore production at the facility, but does not have a targeted date for getting it back up to full capacity. The highest output production line at the factory, which makes intravenous equipment, has restarted. That production line accounts for 25% of all production at the factory.

 

Write to Rob Curran at rob.curran@wsj.com

 

(END) Dow Jones Newswires

November 08, 2024 07:53 ET (12:53 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10